H.C. Wainwright Downgrades Kazia Therapeutics (KZIA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts KZIA Hot Sheet
Price: $8.08 --0%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
H.C. Wainwright analyst Sean Lee downgraded Kazia Therapeutics (NASDAQ: KZIA) from Buy to Neutral.
For an analyst ratings summary and ratings history on Kazia Therapeutics click here. For more ratings news on Kazia Therapeutics click here.
Shares of Kazia Therapeutics closed at $1.92 yesterday.
You May Also Be Interested In
- BofA Securities Downgrades Central Bancompany (CBC) to Neutral
- Keefe, Bruyette & Woods Downgrades CleanSpark Inc. (CLSK) to Market Perform
- Keefe, Bruyette & Woods Downgrades Cipher Mining (CIFR) to Market Perform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
